S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Darwin Global Management/Q4 2023

Darwin Global Management

Period: Q4 2023 Β· Filed: 2024-02-14
View on SEC EDGAR β†—
AUM
$510M
Total portfolio value
Positions
8
Reported securities
Top Holding
AMAM
46.6% $237.7M
QoQ Changes
+8 / -3
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 8 positions

⚠️ Performance % calculated from filing date ( 2024-02-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
AMAMAMBRX BIOPHARMA INC$237.7M46.64%β€”β€”
46.6%
TGTXTG THERAPEUTICS INC$69.1M13.57%$17.04$53.31+212.8%
13.6%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$62.8M12.32%$59.55$18.95-68.2%
12.3%
CYTKCYTOKINETICS INC$50.1M9.83%$84.12$86.49+2.8%
9.8%
KROSKEROS THERAPEUTICS INC$42.2M8.28%$43.13$11.26-73.9%
8.3%
PCVXVAXCYTE INC$36.4M7.15%$62.94$58.39-7.2%
7.2%
SWTXSPRINGWORKS THERAPEUTICS INC$7.0M1.38%β€”β€”
1.4%
NUVLNUVALENT INC$4.3M0.83%$76.10$123.73+62.6%
0.8%

Quarter-on-Quarter Activity

Q4 2023 vs. Q3 2023

New Positions (8)

TickerIssuerNotionalSince Filing
AMAMAMBRX BIOPHARMA INC$237.7M
TGTXTG THERAPEUTICS INC$69.1M+212.8%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$62.8M-68.2%
CYTKCYTOKINETICS INC$50.1M+2.8%
KROSKEROS THERAPEUTICS INC$42.2M-73.9%
PCVXVAXCYTE INC$36.4M-7.2%
SWTXSPRINGWORKS THERAPEUTICS INC$7.0M
NUVLNUVALENT INC$4.3M+62.6%

Exited Positions (3)

TickerIssuerNotional
AMAMAMBRX BIOPHARMA INC$191.9M
IMVTIMMUNOVANT INC$69.8M
ARGXARGENX SE$22.4M

Increased

None this quarter

Trimmed

None this quarter

← Back to Hedge Funds
Darwin Global Management Q4 2023 13F Filing β€” Holdings & Portfolio | MarketsFN